Elias Jabbour, MD, and Dennis Kim, MD, discuss data for recent olverembatininb and its place in CML management.
Dennis Kim, MD
Advertisement
Kim is an associate professor at the Institute of Medical Science at the University of Toronto in Canada.
Articles by Dennis Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
China's NMPA Approves Pirtobrutinib Across CLL
5